RecruitingDiabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Eligible age
1–35 yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
Sponsor: Eli Lilly and Company
You may qualify if…
- ✓ Have a history of at least one documented occasion of at least two diabetes-related autoantibodies, AND one occasion of at least two diabetes-related autoantibodies obtained at screening or prescreening
- ✓ Have Stage 1b or Stage 2 type 1 diabetes
- ✓ Have a body weight of ≥8 kilograms (kg) (18 pounds) at screening
You may not qualify if…
- ✕ Have any other type of diabetes
- ✕ Have uncontrolled high blood pressure
- ✕ Have had a heart attack, heart disease, stroke, or heart failure
- ✕ Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
- ✕ Have a current or recent clinically serious infection
Where it's recruiting
Florida
Tallahassee · Tampa
Iowa
Iowa City · West Des Moines
Kentucky
Louisville
Pennsylvania
Philadelphia
Virginia
Charlottesville
Source: ClinicalTrials.gov · NCT07222137 · last updated 2026-06-23